Cargando…

Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa

BACKGROUND: This post hoc subanalysis examined outcomes in adult patients with Morquio A (mucopolysaccharidosis IVA) who received enzyme replacement therapy (ERT) with elosulfase alfa over a 120-weeks period. Patients ≥18 years of age evaluated in an open-label, long-term extension study of elosulfa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, D., Giugliani, R., Guffon, N., Jones, S. A., Mengel, K. E., Parini, R., Matousek, R., Hawley, S. M., Quartel, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442692/
https://www.ncbi.nlm.nih.gov/pubmed/28535791
http://dx.doi.org/10.1186/s13023-017-0634-0
_version_ 1783238446151630848
author Hughes, D.
Giugliani, R.
Guffon, N.
Jones, S. A.
Mengel, K. E.
Parini, R.
Matousek, R.
Hawley, S. M.
Quartel, A.
author_facet Hughes, D.
Giugliani, R.
Guffon, N.
Jones, S. A.
Mengel, K. E.
Parini, R.
Matousek, R.
Hawley, S. M.
Quartel, A.
author_sort Hughes, D.
collection PubMed
description BACKGROUND: This post hoc subanalysis examined outcomes in adult patients with Morquio A (mucopolysaccharidosis IVA) who received enzyme replacement therapy (ERT) with elosulfase alfa over a 120-weeks period. Patients ≥18 years of age evaluated in an open-label, long-term extension study of elosulfase alfa (modified per protocol [MPP], n = 32; intent-to-treat [ITT], n = 37; MOR-005; NCT01415427) were compared with the ≥18-year-old untreated population with 2-years follow-up from a Morquio A natural history study (n = 10; MorCAP; NCT00787995). The MOR-005 MPP population excluded patients who underwent orthopedic surgical procedures or were noncompliant with study protocol (defined as missing ≥20% of ERT infusions). No MorCAP patients underwent orthopedic surgical procedures during the relevant time period. Endurance was assessed by the 6-min walk test (6MWT) and 3-min stair climb test (3MSCT). Activities of daily living (ADLs) were assessed by the MPS Health Assessment Questionnaire (MPS HAQ). RESULTS: Least squares (LS) mean (SE) 6MWT distances increased by 34.9 (11.7) m (MPP) and 30.5 (10.8) m (ITT) by week 120; LS mean (SE) change in 3MSCT at week 120 was 6.7 (1.8) stairs/min (MPP) and 5.9 (1.7) stairs/min (ITT). MorCAP patients showed no improvement in 6MWT distance or 3MSCT over a similar period of time. Pulmonary function measures remained unchanged in both MOR-005 and MorCAP adults. All MPS HAQ domain scores improved in MOR-005 adults, whereas MorCAP adults had unchanged caregiver assistance and mobility outcomes and worsened self-care outcomes. CONCLUSIONS: Long-term ERT in adult patients with Morquio A was associated with increased endurance and improvement in performance of ADLs. TRIAL REGISTRATION: Trial Registration NCT01415427. Name of registry: Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome). Registered 8 August 2011, retrospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-017-0634-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5442692
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54426922017-05-25 Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa Hughes, D. Giugliani, R. Guffon, N. Jones, S. A. Mengel, K. E. Parini, R. Matousek, R. Hawley, S. M. Quartel, A. Orphanet J Rare Dis Research BACKGROUND: This post hoc subanalysis examined outcomes in adult patients with Morquio A (mucopolysaccharidosis IVA) who received enzyme replacement therapy (ERT) with elosulfase alfa over a 120-weeks period. Patients ≥18 years of age evaluated in an open-label, long-term extension study of elosulfase alfa (modified per protocol [MPP], n = 32; intent-to-treat [ITT], n = 37; MOR-005; NCT01415427) were compared with the ≥18-year-old untreated population with 2-years follow-up from a Morquio A natural history study (n = 10; MorCAP; NCT00787995). The MOR-005 MPP population excluded patients who underwent orthopedic surgical procedures or were noncompliant with study protocol (defined as missing ≥20% of ERT infusions). No MorCAP patients underwent orthopedic surgical procedures during the relevant time period. Endurance was assessed by the 6-min walk test (6MWT) and 3-min stair climb test (3MSCT). Activities of daily living (ADLs) were assessed by the MPS Health Assessment Questionnaire (MPS HAQ). RESULTS: Least squares (LS) mean (SE) 6MWT distances increased by 34.9 (11.7) m (MPP) and 30.5 (10.8) m (ITT) by week 120; LS mean (SE) change in 3MSCT at week 120 was 6.7 (1.8) stairs/min (MPP) and 5.9 (1.7) stairs/min (ITT). MorCAP patients showed no improvement in 6MWT distance or 3MSCT over a similar period of time. Pulmonary function measures remained unchanged in both MOR-005 and MorCAP adults. All MPS HAQ domain scores improved in MOR-005 adults, whereas MorCAP adults had unchanged caregiver assistance and mobility outcomes and worsened self-care outcomes. CONCLUSIONS: Long-term ERT in adult patients with Morquio A was associated with increased endurance and improvement in performance of ADLs. TRIAL REGISTRATION: Trial Registration NCT01415427. Name of registry: Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome). Registered 8 August 2011, retrospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-017-0634-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-23 /pmc/articles/PMC5442692/ /pubmed/28535791 http://dx.doi.org/10.1186/s13023-017-0634-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hughes, D.
Giugliani, R.
Guffon, N.
Jones, S. A.
Mengel, K. E.
Parini, R.
Matousek, R.
Hawley, S. M.
Quartel, A.
Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa
title Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa
title_full Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa
title_fullStr Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa
title_full_unstemmed Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa
title_short Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa
title_sort clinical outcomes in a subpopulation of adults with morquio a syndrome: results from a long-term extension study of elosulfase alfa
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442692/
https://www.ncbi.nlm.nih.gov/pubmed/28535791
http://dx.doi.org/10.1186/s13023-017-0634-0
work_keys_str_mv AT hughesd clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa
AT giuglianir clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa
AT guffonn clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa
AT jonessa clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa
AT mengelke clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa
AT parinir clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa
AT matousekr clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa
AT hawleysm clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa
AT quartela clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa